- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 5 - Recognizing and Addressing Factors Related to Nonadherence
During this segment, Maria Lopes, MD, MS, explains that cost is not the only factor that is associated with treatment nonadherence in patients with diabetes and obesity. Dr Lopes notes that cost is usually number 3 on the list of reasons why patients do not take medicine as prescribed.
Dr Lopes explains that nonadherence is multifactorial; other factors that contribute to nonadherence include the development of troublesome side effects, denial of the disease diagnosis, healthcare disparities, and psychosocial issues including depression. She notes the importance of individualized treatment.
Yehuda Handelsman, MD, FACP, FACE, FNLA, discusses the relationship between adherence and overall outcomes. He explains that poor adherence rates have been associated with poor outcomes for patients in several disease categories including diabetes.
Dr Handelsman emphasizes the need to improve patient adherence and highlights the results of a published study that determined that 33% of patients never visit the pharmacy to fill a prescription.
To address patient nonadherence issues, Dr Lopes believes that regardless of treatment response or the success rates of pharmacotherapy options, patients need to receive continued support from healthcare professionals.
Kari Uusinarkaus, MD, FAAFP, FNLA, further explains how health literacy is related to adherence, and suggests that physicians need to speak to patients on a level that patients can understand.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
From Red Tape to Relief: Rewriting the Rules of Prior Authorization
June 23rd 2025Up to 257 million Americans could benefit from these prior authorization reforms that could have cross-market implications on health care plans administered through commercial insurers, Medicare Advantage, and Medicaid.
Read More
